Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIIPL Tdap-IPV versus Boostrix-IPV booster vaccine study
ACTRN12620000848909Phase 2Terminated
- Sponsor
- Serum Institute of India
- Start
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of SIIPL Tdap-IPV in Tetanus, diphtheria, pertussis and 1 more, sponsored by Serum Institute of India. Primary endpoints: Phase I reactogenicity and safety and Phase II reactogenicity and safety. Started Jul 2020; status: terminated.
02
Drugs
SIIPL Tdap-IPV
03
Conditions
Tetanusdiphtheriapertussispoliomyelitis
Beyond the preview
Go deeper on ACTRN12620000848909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000848909.